Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-MSCs Exosome Injection in Acute-on-Chronic Liver Failure
NCT07409259Phase 1Active, not recruiting
- Sponsor
- The Third Affiliated Hospital of Sun Yat-sen University
- Start
- Jan 2026
- Primary completion
- Aug 2027
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of placenta-derived mesenchymal stem cell-derived extracellular vesicles in acute-on-chronic liver failure (ACLF) (2 arms), sponsored by The Third Affiliated Hospital of Sun Yat-sen University. Primary endpoint: 12-Week Survival Rate. Started Jan 2026; status: active, not recruiting.
02
Drugs
placenta-derived mesenchymal stem cell-derived extracellular vesicles
03
Conditions
acute-on-chronic liver failure (ACLF)
Beyond the preview
Go deeper on NCT07409259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07409259.